



See the Difference: SCS Therapy That Succeeds Where Others Fail



For patients who haven't achieved satisfactory pain relief with other spinal cord stimulator (SCS) systems, Boston Scientific's SCS therapy offers another chance for relief.

Built on 20 years of expertise, extensive clinical evidence, and real-world outcomes, Boston Scientific's SCS therapy is designed to deliver meaningful, lasting pain relief - even for patients who haven't responded to other therapies. With multiple therapy options to address patients' unique pain, the WaveWriter Alpha™ Spinal Cord Stimulator (SCS) System is engineered to get it right the first time.

DIFFERENT OUTCOMES: THE DATA


In two studies, Boston Scientific salvaged 60% of failed SCS trials and implants^{1,2}

The majority of patients studied who did not respond to another manufacturer's SCS therapy found pain relief when their leads were connected to the Boston Scientific SCS System:

- 60% salvage success for failed trials¹
- 60% salvage success for failed implants²

Long-Term Salvage Success

In a published clinical study, salvage implant patients reported durable pain relief out to an average of 1.4 years.²




NOW FDA APPROVED

First and only MRI conditional adapters in SCS

Maintain full-body MRI access with the first MRI conditional adapters, offered exclusively by Boston Scientific.*† Connect to already implanted leads from other manufacturers, and experience the difference.

- **Connect to Medtronic and Abbott trials and implants[‡]**
M8 and S8 MRI Conditional Adapters
- **Direct connect for Nevro trials and implants[§]**
MRI conditionality not evaluated for direct connect



OFFER YOUR PATIENTS A PROFOUND SOLUTION

Boston Scientific offers profound pain relief, proven by clinical data, and is different. Fast-Acting Sub-perception Therapy (FAST™ Therapy) provides relief in as little as 2 minutes and is sustained for more than 2 years, offering clinical and real-world benefits.^{3-7***} It succeeds where others fail and gets it right the first time.

Trial Optimization with FAST Therapy

- Maximize the patient's SCS trial experience. A slow 2-day wash-in period wastes ~30% of a 7-day trial.** FAST Therapy is designed to deliver profound pain relief in as little as two minutes, allowing quick confirmation that your patients are experiencing relief.^{3,4***}
- Provide the ability to be flexible on SCS trial duration. For some high-risk patients like those on blood thinners, physicians can shorten the trial without shortening the amount of relief that the patient gets to experience.

***Disclaimer: These outcomes reflect approximated data as determined in the referenced studies.

[View Boston Scientific Spinal Cord Stimulator System Indications, Safety, and Warnings](#)

Warning: Stimulation modes. Only paresthesia-based stimulation mode has been evaluated for effectiveness in the diabetic peripheral neuropathy (DPN) population.

*MRI Conditional under specified conditions.

**2 days is approximately 30% of a 7-day trial per 2 days / 7 days = 0.285 ≈ 30%.

†ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems" & "ImageReady™ MRI Full Body Guidelines for WaveWriter Alpha™ and WaveWriter Alpha™ Prime Spinal Cord Stimulator Systems with Adapters". Refer to <https://www.bostonscientific.com/elabeling/us/en/home.html> for more information.

MRI Guidelines for Medtronic Neurostimulation Systems for Chronic Pain. M939858A010

1.5 Tesla and 3 Tesla Magnetic Resonance Imaging (MRI) Guidelines for the SENZA®, SENZA II® & SENZA Omnia™ Systems. 11096

MRI Procedure Information For Abbott Medical MR Conditional Neurostimulation Systems. ARTEN600090483 A

‡Refer to the Precision M8 Adapter Directions for Use for indications, warnings and cautions. The Precision M8 Adapter is compatible with the following Medtronic lead and extension model numbers: 39286, 39565, 3778, 3878, 3777, 3877, 3776, 3876, 3874, 3873, 3875, 37081, 37083, 37082, 977A160, 977A175, 977A190, 977A260, 977A275, 977A290, 977D160, 977D260, 977C165, 977C265, 977C190, 977C290

Refer to the "Precision™ S8 Adapter Directions for Use" for indications, warnings and cautions. The Precision™ S8 Adapter is compatible with the following St Jude Lead, Adapter and Extension model numbers: 3283, 3268, 3269, 3280, 3244, 3262, 3263, 3245, 3264, 3265, 3208, 3210, 3288, 3289, 3214, 3219, 3228, 3183, 3186, 3189, 3191, 3086, 3286, 2283, 3341, 3342, 3343, 3346, 3382, 3383, 3386.

§The Boston Scientific SCS Implantable Pulse Generators, OR Cables, and Lead Extensions can be connected to the following compatible Nevro Leads and Lead Extensions: LEAD2008-25B, LEAD2008-35B, LEAD2008-60B, LEAD1058-30B, LEAD1058-50B, LEAD1058-70B, LEAD1058-90B, TLEAD1058-50B, TLEAD1058-70B, TLEAD1058-90B. **Warning:** The Nevro Leads and Lead Extensions have not been tested for compatibility with an MRI environment when used with the Boston Scientific SCS Systems.

For a list of compatible mobile devices, visit www.myscsgojourney.com/mySCSGO. The mySCS™ GO Therapy Controller Application is compatible with the WaveWriter Alpha Spinal Cord Stimulation System only.

In the initial subperception RCT (WHISPER Study), subperception stimulation was demonstrated to be safe and effective in patients who have been treated successfully with conventional, paresthesia-inducing stimulation for at least six months. Full stimulation parameter ranges and options for both paresthesia-based and subperception therapy (such as FAST, Contour™ Programming Algorithm, and other programmable parameters) are available for clinician's use throughout the patient's experience and treatment with SCS.

Data releases and publications from studies such as FAST, WaveWriter-SOLIS RCT, RELIEF and PRO have all included patients who successfully used subperception therapy from the start of their experience and treatment with SCS.

References:

1. Haider N, Ligham D, Quave B, et al. Spinal cord stimulation (SCS) trial outcomes after conversion to a multiple waveform scs system. *Neuromodulation*. 2018;21(5):504-507.
2. Rigoard P, Billot M, Bougeard R, et al. Improved outcomes and therapy longevity after salvage using a novel spinal cord stimulation system for chronic pain: multicenter, observational, European case series. *J Clin Med*. 2024;13(4):1079.
3. Gage E., et al. Rapid Onset of Analgesia during Trial Period Utilizing Fast-Acting Sub-Perception Therapy SCS [Abstract] NANS 2023 Annual Meeting, Jan 12-15, 2023.
4. Anitescu M., et al. Utilizing SCS Designed to Engage Surround Inhibition Using Fast-Acting Sub-Perception Therapy (FAST): Prospective, Multicenter, Long-Term Outcomes [Abstract] NANS 2025 Annual Meeting, Jan 30-Feb 1, 2025.
5. Metzger C, Hammond B, Ferro R, et al. Two-year outcomes using fast-acting sub-perception therapy for spinal cord stimulation: results of a real-world multicenter study in the United States. *Expert Rev Med Devices*. 2025;22(2):155-164.
6. Bayerl S, Paz-Solis J, Matis G, et al. Two-year outcomes using fast-acting, sub-perception therapy for spinal cord stimulation: a European, real-world, multicenter experience. *J Clin Med*. 2024;13(22):6999.
7. Ferro R, North J, Kranenburg A, et al. Automated neural dosing for fast-acting subperception therapy: sustained spinal cord stimulation outcomes from a multicenter study. *Pain Ther*. 2025;14(4):1417-1429.

**Boston
Scientific**
Advancing science for life™

25155 Rye Canyon Loop
Valencia, CA 91355 USA

Copyright ©2026 by
Boston Scientific Corporation
or its affiliates. All rights reserved.

NM-2371511-AA